NCT04935047 is a NA clinical trial of Multilingual Support in Language, sponsored by Oslo Metropolitan University.

Who is sponsoring NCT04935047?

NCT04935047 is sponsored by Oslo Metropolitan University.

What drugs are being tested in NCT04935047?

Interventions in NCT04935047: Multilingual Support.

Is NCT04935047 still recruiting?

NCT04935047 is currently completed. Last updated 31 March 2023.

Last reviewed 2023-03-31 · How we verify

NCT04935047

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Trial of Multilingual Support Intervention

Completed NA Last updated 31 March 2023

What this trial tests

NA trial testing Multilingual Support in Language in 49 participants. Completed in 30 June 2022.

Timeline

16 August 2021

Primary endpoint
27 May 2022

30 June 2022

Quick facts

Lead sponsor	Oslo Metropolitan University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	49
Start date	16 August 2021
Primary completion	27 May 2022
Estimated completion	30 June 2022
Sites	3 locations across Norway

Drugs / interventions tested

Multilingual Support

Conditions studied

Language — all drugs for Language →

Sponsor

Oslo Metropolitan University

Who can join

18 and older, any sex, with Language. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a feasibility study and a pilot trial of a multilingual support intervention with the aim to improve language training for Norwegian refugees by systematically using the participants' primary language to support the learning of the new language. The study is conducted in three Norwegian municipalities with the aim to evaluate feasibility for a full-scale randomised controlled trial. The pilot trial will include at least 30 participants, with two thirds allocated to the treatment group and one third to the control group. The intervention will be implemented as an add on to ordinary classroom settings. The treatment group will receive seven hours multilingual support weekly. The control group will receive the same amount of support, but from a person without multilingual qualifications. The Norwegian Directorate of Integration and Diversity (IMDi) are funding the project and have reviewed the protocol.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Language

Currently open trials in the same condition.

NCT06974279 — Post-Stroke Aphasia TMS · NA · recruiting
NCT06471127 — Neuroplasticity Biomarkers in Aphasia · NA · recruiting
NCT06479278 — Talk With Me Baby to Enhance the Early Home Language Environment · NA · recruiting
NCT06608680 — Timing and Facilitation Effects of Theta-Burst Stimulation in the Reading and Language Networks · NA · recruiting
NCT05222594 — Computational Neuroscience of Language Processing in the Human Brain · NA · recruiting

Other Oslo Metropolitan University trials

Trials by the same sponsor.

NCT06578260 — Support Groups - a Model for Social Inclusion and Reduction of Bullying in School · NA · recruiting
NCT05784324 — COMPRESSED - A Longitudinal Study of Compressed Work Schedules Within the Health, Care and Welfare Services · not yet recruiting
NCT05895604 — The Mother in Norway Study · NA · recruiting
NCT06117098 — Mobile App for Risk Reduction of Type 2 Diabetes · NA · unknown
NCT05697120 — Long-term Effects of Individualized Follow-up With an App for One Year · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04935047 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oslo Metropolitan University
Last refreshed: 31 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04935047.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing